Search Results 71-80 of 16564 for B cell lymphomas

1. Zhi Zhang Yang, M.D. - Mayo Clinic Faculty Profiles

   In B-cell non-Hodgkin's lymphoma, cells other than tumor cells are commonly seen within tumor tissue. These cells include T lymphocytes that seem to be more ...

2. A Study to Evaluate Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) - Mayo Clinic

   The purpose of tis study is to evaluate whether adding brentuximab vedotin helps two drugs work better to treat patients with diffuse large B-cell lymphoma ( ...

3. Axicabtagene Ciloleucel versus Standard of Care Therapy as First-Line Therapy in High-Risk Large B-Cell Lymphoma - Mayo Clinic

   Clinical Trials · Axicabtagene Ciloleucel versus Standard of Care Therapy as First-Line Therapy in High-Risk Large B-Cell Lymphoma · More about research at Mayo ...

4. A Study of JNJ-90009530 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (r/​r B-NHL) - Mayo Clinic

   The goal of this multicenter study is to test JNJ-90009530 in Relapsed or Refractory Non-Hodgkin Lymphoma Patients. The main questions the study aims to answer ...

5. A Study to Compare the Effectiveness and Safety of JCAR017 to Standard of Care in Adult Subjects With High-risk, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas - Mayo Clinic

   ... B-cell Non-Hodgkin Lymphomas. Print details. Share; Facebook · Twitter. Overview; Participation eligibility; Participating Mayo Clinic info; More information ...

6. Sorting Out T-Cell Lymphoma - Mayo Clinic News Network

   Although B cells and T cells can give rise to malignancies or lymphomas, T-cell lymphoma is the rarer disease, making up less than 15% of all Non-Hodgkin ...

7. A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) - Mayo Clinic

   A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) · Share · Facebook ...

8. CAR-T Cell Therapy Program

   Aggressive B-cell lymphoma not otherwise specified (NOS); Mantle cell lymphoma; Follicular lymphoma; Multiple myeloma. People who have relapsed or refractory ...

9. Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma - Mayo Clinic

   Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma.

10. Compare the Efficacy and Safety of Golcadomide Plus R-CHOP vs Placebo Plus RCHOP in Participants with Previously Untreated High-risk Large B-cell Lymphoma - Mayo Clinic

    Compare the Efficacy and Safety of Golcadomide Plus R-CHOP vs Placebo Plus RCHOP in Participants with Previously Untreated High-risk Large B-cell Lymphoma.